The Place of Sulfonylureas in Guidelines: Why Are There Differences?
- PDF / 627,539 Bytes
- 10 Pages / 595.276 x 790.866 pts Page_size
- 17 Downloads / 213 Views
REVIEW
The Place of Sulfonylureas in Guidelines: Why Are There Differences? Aslam Amod
Received: January 29, 2020 Ó The Author(s) 2020
ABSTRACT Key Summary Points This review describes a presentation at a recent symposium entitled ‘‘SUs in the treatment of T2DM: a fresh look and new insights’’ on Wednesday September 18, 2019 at the 55th Annual Meeting of the European Association for the Study of Diabetes (EASD) in Barcelona, Spain. It examines the current role of sulfonylureas (SUs) in the management of type 2 diabetes mellitus (T2DM) and gives the author’s personal perspective of how this therapeutic class has performed in both local and international guidelines. The place of SUs within current guidelines is highlighted, and a critical appraisal of the reasons for the differences between guidelines given. Finally, comparison of evidence-based guidelines and consensus reports is discussed.
Keywords: Consensus report; Evidence-based guidelines; Sulfonylureas; Type 2 diabetes mellitus Enhanced Digital Features To view enhanced digital features for this article go to https://doi.org/10.6084/ m9.figshare.12030321. A. Amod (&) Department of Diabetes and Endocrinology, Life Chatsmed Garden Hospital, Nelson R Mandela School of Medicine, Durban, South Africa e-mail: [email protected]
Key guidelines on the treatment of type 2 diabetes mellitus (T2DM) include those from the World Health Organization (WHO) and the International Diabetes Federation (IDF) and are evidence-based, whereas the popular joint report from the European Association for the Study of Diabetes (EASD) and the American Diabetes Association (ADA) is a consensus Numerous regional guidelines on diabetes treatment are currently available, including the scientifically rigorous and independent National Institute for Health and Care Excellence (NICE) guideline in the UK This review provides a critical appraisal of differences between various guidelines, and compares evidence-based guidelines with consensus reports, on the role of sulfonylureas (SUs) in the management of T2DM Most international and regional guidelines differentiate between different SUs SUs remain widely recommended as safe and effective glucose-lowering agents, with low absolute rates of severe hypoglycaemia
Diabetes Ther
INTRODUCTION The four main internationally recognised guidelines or consensus reports for the treatment of type 2 diabetes mellitus (T2DM) are from the European Association for the Study of Diabetes (EASD)/American Diabetes Association (ADA) [1], Diabetes Canada [2], the World Health Organization (WHO) [3] and the International Diabetes Federation (IDF) [4]. Of these, EASD/ADA is the most popular despite it being only a consensus report, and not meeting the Institute of Medicine requirements for trustworthy guidelines [5]. The current article describes the place of sulfonylureas (SUs) within current international guidelines for the management of T2DM, and critically examines the quality of the guideline development process and of the evidence to support those recommen
Data Loading...
